Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Sep 02, 2022 1:00pm
364 Views
Post# 34938597

RE:Numbers & Percentages of Evaluable Patients

RE:Numbers & Percentages of Evaluable Patients

Excellent summary and comparison.  When we look at these numbers, we must remember that they include the 1set of 12 undertreated where 5 were dropped without a 2nd optimized treatment and 1 patient who died of unrelated cause.  So at 360 days the 9 CR out of 26 could really be 9 out of 20 with 3 out of 20 PR.  Numbers are getting better quite significantly, it this keeps up we can really shine at next data readout PR.  All IMHO

 


Eoganacht wrote:  

May 30, 2022 - Number of Patients
           
  90 Days 180 Days 270 Days 360 Days 450 Days
CR 17 16 10 5 5
PR 8 7 2 4 2
TR 25 23 12 9 7
NR 12 9 14 14 15
Total Evaluable 37 32 26 23 22
           
May 30, 2022 - Percentages
           
  90 Days 180 Days 270 Days 360 Days 450 Days
CR 46% 50% 39% 22% 23%
PR 22% 22% 8% 17% 9%
TR 68% 72% 46% 39% 32%
NR 32% 28% 54% 61% 69%
Total Evaluable 37 32 26 23 22
           
August 29, 2022 - Number of Patients
           
  90 Days 180 Days 270 Days 360 Days 450 Days
CR 19 16 13 9 5
PR 6 9 7 3 3
TR 25 25 20 12 8
NR 13 9 12 14 16
Total Evaluable 38 34 32 26 24
           
August 29, 2022 -Percentages
           
  90 Days 180 Days 270 Days 360 Days 450 Days
CR 50% 47% 41% 35% 21%
PR 16% 26% 22% 12% 13%
TR 66% 74% 63% 46% 33%
NR 34% 26% 37% 54% 67%
Total Evaluable 38 34 32 26 24
 


<< Previous
Bullboard Posts
Next >>